Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
25 and 50 mg diclofenac K film coated immediate release tablets More
Topical Diclofenac formulations for the treatment of inflammatory and painful conditions More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
25mg dosage strenght for the OTC market in film coated tablets More
Capsaicin, the active ingredient found in red-hot peppers, is used mainly for the relief of chronic pain of rheumatoid arthritis and osteoarthritis More
The First Line of Therapy in Severe Migraine Attacks More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Related Reports
Market Research Reports provided by reports.iptechex.com
Mar 2011 - 23 pages - $5,700
Sep 2008 - $2,500
Nov 2010 - 40 pages - $500
Nov 2010 - 1168 pages - $1,495
Nov 2010 - 50 pages - $2,000
Jan 2008 - 180 pages - $3,500
Oct 2010 - 169 pages - $3,500
Dec 2010 - 84 pages - $500
Oct 2011 - 131 pages - $3,500
Jul 2011 - 54 pages - $3,800
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us